Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 3/2013

01.06.2013 | ALLERGIC AND IMMUNOLOGIC DISORDERS OF THE EYE AND NERVOUS SYSTEM (CH KATELARIS, SECTION EDITOR)

New Agents for Treating Dry Eye Syndrome

verfasst von: Simon E. Skalicky, Con Petsoglou, Avinash Gurbaxani, Clare L. Fraser, Peter McCluskey

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Dry eye syndrome (DES) is characterized by an inadequate volume and/or quality of tears resulting in chronic ocular surface irritation and inflammation. Affecting up to 30 % of adults, DES has a considerable impact on visual function and quality of life. DES may complicate allergic ocular disease and allergy medication may exacerbate DES. The pathophysiology of DES involves osmotic, mechanical and inflammatory insults to the tear film, epithelium and subepithelial nerve plexus. Various immune-related molecular targets have been the focus of research aimed at developing new therapeutic agents for treating DES. This article provides an overview of established, new and future agents for treating DES.
Literatur
1.
Basic and Clinical Science Course. Section 8. External disease and cornea, American Academy of Ophthalmology, 2008.
2.
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75–92.
3.
• Yavuz B, Bozdağ Pehlivan S, Unlü N. An overview on dry eye treatment: approaches for cyclosporin a delivery. ScientificWorldJournal. 2012;2012:194848. A concise overview of the pharmacokinetics of topical cyclosporine and new drug delivery systems.
4.
The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):93-107.
5.
Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136(2):318–26.PubMedCrossRef
6.
Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118(9):1264–68.PubMedCrossRef
7.
Brewitt H, Sistani F. Dry eye disease: the scale of the problem. Surv Ophthalmol. 2001;45 Suppl 2:S199–202.PubMedCrossRef
8.
9.
Guillon M, Maissa C. Contact lens wear affects tear film evaporation. Eye Contact Lens. 2008;34(6):326–30.PubMedCrossRef
10.
Yee RW, Sperling HG, Kattek A, Paukert MT, Dawson K, Garcia M, Hilsenbeck S. Isolation of the ocular surface to treat dysfunctional tear syndrome associated with computer use. Ocul Surf. 2007;5(4):308–15.PubMedCrossRef
11.
Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care. 2008;14(3 Suppl):S102–6.PubMed
12.
Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. The CLAO Journal. 1995;21(4):221–32.PubMed
13.
• Pult H, Purslow C, Murphy PJ. The relationship between clinical signs and dry eye symptoms. Eye (Lond). 2011;25(4):502–10. A 47-patient cohort study comparing clinical symptoms of dry eye with new and traditional clinical tests. When used in combination, these tests correlate with symptomatic severity of dry eye syndrome.
14.
Li M, Gong L, Sun X, Chapin WJ. Anxiety and depression in patients with dry eye syndrome. Curr Eye Res. 2011;36(1):1–7.PubMedCrossRef
15.
Miljanović B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143(3):409–15.PubMedCrossRef
16.
McGinnigle S, Naroo SA, Eperjesi F. Evaluation of dry eye. Surv Ophthalmol. 2012;57(4):293–316.PubMedCrossRef
17.
Luo L, Li DQ, Corrales RM, Pflugfelder SC. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens. 2005;31(5):186–93.PubMedCrossRef
18.
De Paiva CS, Pangelinan SB, Chang E, et al. Essential role for c-Jun N-terminal kinase 2 in corneal epithelial response to desiccating stress. Arch Ophthalmol. 2009;127(12):1625–31.PubMedCrossRef
19.
Li DQ, Luo L, Chen Z, Kim HS, Song XJ, Pflugfelder SC. JNK and ERK MAP kinases mediate induction of IL-1β, TNF-α and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res. 2006;82(4):588–96.PubMedCrossRef
20.
•• Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130(1):90-100. An excellent overview of the immunopathogenesis of dry eye and the associated molecular targets for anti-inflammatory treatment of dry eye syndrome.
21.
El Annan J, Chauhan SK, Ecoiffier T, Zhang Q, Saban DR, Dana R. Characterization of effector T cells in dry eye disease. Invest Ophthalmol Vis Sci. 2009;50(8):3802-3807.
22.
De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2(3):243–53.PubMedCrossRef
23.
Chen YT, Nikulina K, Lazarev S, et al. Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjogren’s syndrome. Am J Pathol. 2010;177(3):1333–43.PubMedCrossRef
24.
De Paiva CS, Villarreal AL, Corrales RM, et al. Dry eye–induced conjunctival epithelial sqγuamous metaplasia is modulated by interferon-γ. Invest Ophthalmol Vis Sci. 2007;48(6):2553–60.PubMedCrossRef
25.
Yeh S, Song XJ, Farley W, Li DQ, Stern ME, Pflugfelder SC. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest Ophthalmol Vis Sci. 2003;44(1):124–9.PubMedCrossRef
26.
Benıtez-Del-Castillo JM, Acosta MC, Wassfi MA, et al. Relation between corneal innervation with confocal microscopy and corneal sensitivity with noncontact esthesiometry in patients with dry eye. Invest Ophthalmol Vis Sci. 2007;48(1):173–81.PubMedCrossRef
27.
Hosal BM, Ornek N, Zilelioğlu G, Elhan AH. Morphology of corneal nerves and corneal sensation in dry eye: a preliminary study. Eye (Lond). 2005;19(12):1276–9.CrossRef
28.
Yoon KC, Jeong IY, Park YG, Yang SY. Interleukin-6 and tumor necrosis factor-α levels in tears of patients with dry eye syndrome. Cornea. 2007;26(4):431–7.PubMedCrossRef
29.
• Enrıquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis. 2010;16:862–73. An evaluation of cytokines and other inflammatory molecules in the tear films of patients with mild-to-moderate dry eye syndrome compared to healthy subjects. Interleukin (IL) 1-receptor antagonist, IL-6, IL-8/CXCL-8 and epidermal growth factor levels correlated with symptoms and signs of dry eye syndrome.
30.
Chotikavanich S, de Paiva CS, Li Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009;50(7):3203–9.PubMedCrossRef
31.
Brignole F, Pisella PJ, Goldschild M, De Saint Jean M, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci. 2000;41(6):1356–63.PubMed
32.
Gao J, Morgan G, Tieu D, et al. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjogrens syndrome-like MRL/lpr mice. Exp Eye Res. 2004;78(4):823–35.PubMedCrossRef
33.
Zheng X, de Paiva CS, Li DQ, Farley WJ, Pflugfelder SC. Desiccating stress promotion of Th17 differentiation by ocular surface tissues through a dendritic cell mediated pathway. Invest Ophthalmol Vis Sci. 2010;51(6):3083–91.PubMedCrossRef
34.
Chauhan SK, Dana R. Role of Th17 cells in the immunopathogenesis of dry eye disease. Mucosal Immunol. 2009;2(4):375–6.PubMedCrossRef
35.
Lee JH, Ahn HS, Kim EK, Kim TI. Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea. 2011;30(2):175–9.PubMedCrossRef
36.
McDonald CC, Kaye SB, Figueiredo FC, Macintosh G, Lockett C. A randomised, crossover, multicentre study to compare the performance of 0.1 % (w/v) sodium hyaluronate with 1.4 % (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond). 2002;16(5):601–7.CrossRef
37.
Brignole F, Pisella PJ, Dupas B, et al. Efficacy and safety of 0.18 % sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch Clin Exp Ophthalmol. 2005;243(6):531–8.PubMedCrossRef
38.
Lemp MA. Management of dry eye. Am J Managed Care. 2008;14:S088–101.
39.
Scaffidi RC, Korb DR. Comparison of the efficacy of two lipid emulsion eyedrops in increasing tear film lipid layer thickness. Eye Contact Lens. 2007;33(1):38–44.PubMedCrossRef
40.
Benelli U. Systane lubricant eye drops in the management of ocular dryness. Clin Ophthalmol. 2011;5:783–90.PubMedCrossRef
41.
Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13.PubMedCrossRef
42.
De Paiva CS, Corrales RM, Villarreal AL, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci. 2006;47(7):2847–56.PubMedCrossRef
43.
Lekhanont K, Leyngold IM, Suwan-Apichon O, Rangsin R, Chuck RS. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B–induced mouse model. Cornea. 2007;26(1):84–9.PubMedCrossRef
44.
Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2003;136(4):593–602.PubMedCrossRef
45.
Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5 %, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444–57.PubMedCrossRef
46.
Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008;92:455–9.PubMedCrossRef
47.
• Zhu L, Zhang C, Chuck RS. Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulium toxin B-induced murine dry eye model. Mol Vis. 2012;18:1803–12. Botulin toxin B-induced mouse tear-deficiency dry eye model has been shown to mimic human non-Sjogren’s disease. In this study, topical fluoromethalone and not NSAIDs reduced staining of tumor necrosis factor α and IL-1β in corneal and conjunctival epithelia.
48.
Congdon N, Schein O, Kulajta P, Lubomski L, Gilbert D, Katz J. Corneal complications associated with topical ophthalmic use of nonsteroidal anti-inflammatory drugs. J Cataract Refract Surg. 2001;27:622–31.PubMedCrossRef
49.
De Paiva CS, Corrales RM, Villarreal AL, Farley WJ, Li DQ, Stern ME, Pflugfelder SC. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83:526–35.PubMedCrossRef
50.
Luo L, Li DQ, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45:4293–301.PubMedCrossRef
51.
Nikodemova M, Watters JJ, Jackson SJ, Yang SK, Duncan ID. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC) alpha/betaII. J Biol Chem. 2007;282(20):15208–16.PubMedCrossRef
52.
Shafaa MW, El Shazly LH, El Shazly AH, El Gohary AA, El Hossary GG. Efficacy of topically applied liposome-bound tetracycline in the treatment of dry eye model. Vet Ophthalmol. 2011;14(1):18–25.PubMedCrossRef
53.
Veldman P, Colby K. Current evidence for topical azithromycin 1 % ophthalmic solution in the treatment of blepharitis and blepharitis-associated ocular dryness. Int Ophthalmol Clin. 2011;51(4):43–52.PubMedCrossRef
54.
Nichols JJ, Bickle KM, Zink RC, Schiewe MD, Haque RM, Nichols KK. Safety and efficacy of topical azithromycin ophthalmic solution 1.0 % in the treatment of contact lens-related dry eye. Eye Contact Lens. 2012;38(2):73–9.PubMedCrossRef
55.
Tauber J, Davitt WF, Bokosky JE, et al. Double-masked, placebo controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004;23:784–92.PubMedCrossRef
56.
• Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K. Diquafosol Ophthalmic Solution Phase 2 Study Group. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese Phase 2 Clinical Trial. Ophthalmology 2012;119(10):1954-60. A randomized, double-masked, multicenter clinical trial comparing topical diquafosol (1 %, n = 96, 3 %, n = 96) to placebo (n = 94). There was a dose-dependent improvement in fluorescein staining and an improvement in symptom score in both treatment groups.
57.
Frist-Larsen K, Isager H, Manthorpe R. Sjogren’s syndrome treated with bromhexine: a randomized clinical study. Br Med J. 1978;1:1579–81.CrossRef
58.
Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J. Therapeutic targets in dry eye syndrome. Drug News Perspect. 2008;21(3):166–76.PubMed
59.
Avni I, Garzozi HJ, Barequet IS, et al. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology. 2010;117(7):1287–93.PubMedCrossRef
60.
Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004;88:1467–74.PubMedCrossRef
61.
Kojima T, Higuchi A, Goto E, Matsumoto Y, Dogru M, Tsubota K. Autologous serum eye drops for the treatment of dry eye diseases. Cornea. 2008;27 Suppl 1:S25–30.PubMedCrossRef
62.
Bradley JC, Simoni J, Bradley RH, McCartney DL, Brown SM. Time- and temperature-dependent stability of growth factor peptides in human autologous serum eye drops. Cornea. 2009;28(2):200–5.PubMedCrossRef
63.
Kojima T, Ishida R, Dogru M, et al. The effect of autologous serum eye drops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol. 2005;139:242–6.PubMedCrossRef
64.
Urzua CA, Vasquez DH, Huidobro A, Hernandez H, Alfaro J. Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. Curr Eye Res. 2012;37(8):684–8.PubMedCrossRef
65.
Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54(3):321–38.PubMedCrossRef
66.
Eckstein LA, Van Quill KR, Bui SK, et al. Cyclosporin a inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells. Invest Ophthalmol Vis Sci. 2005;46:782–90.PubMedCrossRef
67.
Waldmeier PC, Zimmermann K, Qian T, et al. Cyclophilin D as a drug target. Curr Med Chem. 2003;10:1485–506.PubMedCrossRef
68.
Brignole F, Pisella PJ, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6- month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci. 2001;42:90–5.PubMed
69.
Brignole F, Pisella PJ, Goldschild M, et al. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci. 2000;41:1356–63.PubMed
70.
Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120:330–7.PubMedCrossRef
71.
Yoshida A, Fujihara T, Nakata K. Cyclosporin A increases tear fluid secretion via release of sensory neurotransmitters and muscarinic pathway in mice. Exp Eye Res. 1999;68(5):541–6.PubMedCrossRef
72.
Sall K, Stevenson OD, Mundorf TK, et al. CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000;107:631–9.PubMedCrossRef
73.
Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 2000;107(5):967–74.
74.
El Tayar N, Mark AE, Vallat P, et al. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. J Med Chem. 1993;36(24):3757–64.PubMedCrossRef
75.
Liu H, Wang Y, Li S. Advanced delivery of ciclosporin A: present state and perspective. Expert Opin Drug Deliv. 2007;4(4):349–58.PubMedCrossRef
76.
Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in glaucoma patients. Am J Ophthalmol. 2012;153(1):1–9.PubMed
77.
Kanai A, Alba RM, Takano T, et al. The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops. Transplant Proc. 1989;21(1):3150–52. part 3.PubMed
78.
Schechter BA. Ketorolac during the induction phase of cyclosporin-A therapy. J Ocul Pharmacol Ther. 2006;22(2):150–4.PubMedCrossRef
79.
Milani JK, Pleyer U, Dukes A, et al. Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology. 1993;100(6):890–6.PubMed
80.
Dillen K, Bozdag S, Vandervoort J, Ludwig A. Evaluation of the physicochemical characteristics and activity of various kinds of ciprofloxacin HCl-loaded cationic nanoparticles. J Drug Del Sci Tech. 2007;17(1):49–56.
81.
Sárdy M, Ruzicka T, Kuhn A. Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res. 2009;301(1):93–8.PubMedCrossRef
82.
Russell JJ. Topical tacrolimus: a new therapy for atopic dermatitis. Am Fam Physician. 2002;66(10):1899–903.PubMed
83.
Moscovici BK, Holzchuh R, Chiacchio BB, Santo RM, Shimazaki J, Hida RY. Clinical treatment of dry eye using 0.03 % tacrolimus eye drops. Cornea. 2012;31(8):945–9.PubMedCrossRef
84.
85.
Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: How much cause for concern? Br J Dermatol. 2005;153:701–5.PubMedCrossRef
86.
Aragona P, Bucolo C, Spinella R, Giuffrida S, Ferreri G. Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjogren’s syndrome patients. Invest Ophthalmol Vis Sci. 2005;46(12):4474–9.PubMedCrossRef
87.
• Rosenberg ES, Asbell PA. Essential fatty acids in the treatment of dry eye. Ocul Surf. 2010;8(1):18–28. A well-written review of the literature regarding essential fatty acids for the prevention or treatment of dry eye syndrome. All the studies demonstrated that essential fatty acid supplementation resulted in some improvement in dry eye syndrome yet the evidence is not strong.
88.
Barabino S, Rolando M, Camicione P, et al. Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea. 2003;22:97–101.PubMedCrossRef
89.
Rashid S, Jin Y, Ecoiffier T, Barabino S, Schaumberg D, Dana R. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol. 2008;126:219–25.PubMedCrossRef
90.
James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71 Suppl 1:343S–8S.PubMed
91.
Li N, He J, Schwartz CE, Gjorstrup P, Bazan HE. Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J Ocul Pharmacol Ther. 2010;26(5):431–9.PubMedCrossRef
92.
93.
Takeji Y, Urashima H, Aoki A, Shinohara H. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther. 2012;28(3):259–63.PubMedCrossRef
94.
• Fahmy AM, Hardten DR. Treating ocular surface disease: new agents in development. Clin Ophthalmol. 2011;5:465–472. A review of new agents in the treatment of ocular surface disease.
95.
Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010;69:413–6.PubMedCrossRef
96.
Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007;282(28):20059–63.PubMedCrossRef
97.
• Ding C, Nandoskar P, Lu M, Thomas P, Trousdale MD, Wang Y. Changes of aquaporins in the lacrimal glands of a rabbit model of Sjögren's syndrome. Curr Eye Res. 2011;36(6):571–8. Protein and mRNA levels of aquaporin-4 and -5 were assessed in the lacrimal glands of rabbits with induced autoimmune dacryoadenitis compared to age-matched controls. Levels were altered in the diseased lacrimal glands, being greater or less than normal depending on the site (ductal or acinar cells) and aquaporin type (-4 or -5).
98.
Ecoiffier T, El Annan J, Rashid S, Schaumberg D, Dana R. Modulation of integrin α4β1 (VLA-4) in dry eye disease. Arch Ophthalmol. 2008;126(12):1695–9.PubMedCrossRef
99.
Chauhan SK, El Annan J, Ecoiffier T, et al. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol. 2009;182(3):1247–52.PubMed
Metadaten
Titel
New Agents for Treating Dry Eye Syndrome
verfasst von
Simon E. Skalicky
Con Petsoglou
Avinash Gurbaxani
Clare L. Fraser
Peter McCluskey
Publikationsdatum
01.06.2013
Verlag
Current Science Inc.
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 3/2013
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-012-0321-0

Weitere Artikel der Ausgabe 3/2013

Current Allergy and Asthma Reports 3/2013 Zur Ausgabe

ALLERGIC AND IMMUNOLOGIC DISORDERS OF THE EYE AND NERVOUS SYSTEM (CH KATELARIS)

Ocular Myositis

ALLERGIC AND IMMUNOLOGIC DISORDERS OF THE EYE AND NERVOUS SYSTEM (CH KATELARIS, SECTION EDITOR)

Ocular Complications Associated with Systemic Medications Used in Allergy/Immunology Practice

ALLERGENS (RK BUSH, SECTION EDITOR)

Airborne Seafood Allergens as a Cause of Occupational Allergy and Asthma

Allergic and Immunologic Disorders of the Eye and Nervous System (CH Katelaris, Section Editor)

Use of Cyclosporine A and Tacrolimus in Treatment of Vernal Keratoconjunctivitis

ALLERGENS (RK BUSH, SECTION EDITOR)

Virus/Allergen Interactions in Asthma

ALLERGENS (RK BUSH, SECTION EDITOR)

Racial Differences in Allergic Sensitization: Recent Findings and Future Directions

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise